论文部分内容阅读
目的:探讨CA125、CA724联合检测诊断卵巢肿瘤的意义与价值。方法:用化学发光法测定310份血清的CA724、CA125水平,其中80例正常人、230例卵巢肿瘤(良性肿瘤136例、卵巢癌94例)。结果:卵巢癌患者CA125、CA724水平明显高于正常对照组和良性肿瘤组(P<0.01),且随着临床期别的增高,CA125和CA724的阳性率增高;CA125、CA724联合检测的敏感性和特异性优于单独检测,能明显提高早期卵巢癌阳性检出率。结论:CA125、CA724联合检测对早期卵巢癌的诊断和临床分期有重要价值,弥补了单独检测CA125的不足。
Objective: To investigate the significance and value of combined detection of CA125 and CA724 in the diagnosis of ovarian tumors. Methods: The levels of CA724 and CA125 in 310 serum samples were determined by chemiluminescence method. Among them, 80 cases were normal and 230 cases were ovarian tumors (136 cases of benign tumors and 94 cases of ovarian cancer). Results: The levels of CA125 and CA724 in patients with ovarian cancer were significantly higher than those in normal control group and benign tumor group (P <0.01). The positive rates of CA125 and CA724 increased with the increase of clinical stage. The sensitivity of combined detection of CA125 and CA724 And specificity better than single test, can significantly improve the positive detection rate of early ovarian cancer. Conclusion: The combined detection of CA125 and CA724 has important value in the diagnosis and clinical stage of early ovarian cancer, and makes up for the deficiency of detecting CA125 alone.